MedTrace Logo

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

NCT01694277 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 258

Last updated 2020-12-08

No results posted yet for this study

Summary

The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after progression with imatinib.

Conditions

Interventions

DRUG

Masitinib

12 mg/kg/day

DRUG

Sunitinib

50 mg/day

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Axel Le Cesne, M.D., Ph.D · Institute Gustave Roussy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States
  • France
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01694277 on ClinicalTrials.gov